Goldman, Butterwick, Fitzpatrick and Groff
The primary objective is to compare physician-assessed clearance of telangiectatic veins between treatment legs using the Physician Global Aesthetic Improvement Scale (PGAIS). Secondary objectives include assessment of procedural pain, safety outcomes, and patient satisfaction.
This is a prospective, double-blind, split-body, randomized, controlled pilot study enrolling twenty (20) adult subjects. Subjects with reticular veins (≥1 mm) will first undergo pre-treatment with foamed sodium tetradecyl sulfate (STS) using the investigator's standard technique. Subjects without reticular veins will proceed directly to telangiectasia treatment. At a subsequent treatment visit approximately four weeks later, subjects will undergo split-leg sclerotherapy for telangiectatic veins (\<1 mm), with one leg randomized to receive glycerin compounded with 1% lidocaine, and the contra…
Inclusion Criteria: 1. Subjects aged 20-75years. 2. Fitzpatrick skin types I-VI. 3. Presence of lower extremity telangiectatic veins (\<1 mm) suitable for sclerotherapy (reticular veins ≥1 mm can be present but are not required). 4. Duplex ultrasonography negative for saphenous vein reflux in both legs. 5. Willing to undergo split-leg randomization (CG + 1% lidocaine vs CG + 1% lidocaine with epinephrine 1:100,000). 6. Willing and able to comply with all study procedures, including standardized photography, in-person evaluations by a non-treating physician investigator, Day 90 follow-up asses…
Right leg treated with glycerin compounded with 1% lidocaine and epinephrine
Left leg treated with glycerin compounded with 1% lidocaine and epinephrine
Arctuva estimate
Verify or correct the compensation shown for this listing.